Analysis Tools
mortality/aging
 |
• anti-CD4 antibody treated (to delete CD4+ T cells) mice survive longer than untreated or anti-CD8 antibody treated mutant mice, to an average of 55 days
|
|
|
• most untreated and anti-CD8 antibody treated (to delete CD8+ T cells) mice die before day 15 due to scurfy disease
|
growth/size/body
|
|
• decreased body weight in untreated and anti-CD8 antibody treated mutants but not in anti-CD4 antibody treated mutants at day 15
|
|
|
• untreated and anti-CD8 antibody treated mice that survive past 15 days of age exhibit splenomegaly
|
immune system
|
|
• untreated and anti-CD8 antibody treated mice that survive past 15 days of age exhibit splenomegaly
|
|
|
• significantly greater number of activated CD4+CD44+ T cells in the lymph nodes of both untreated and anti-CD8 antibody treated mutant mice
|
|
|
• untreated and anti-CD8 antibody treated mice that survive past 15 days of age exhibit lymphadenopathy
|
hematopoietic system
|
|
• untreated and anti-CD8 antibody treated mice that survive past 15 days of age exhibit splenomegaly
|
|
|
• anti-CD8 antibody treated mutant mice exhibit decreased anemia than untreated mutant mice, although both develop anemia
|
|
|
• untreated and anti-CD8 antibody treated mutants, but not anti-CD4 antibody treated mutants, exhibit decreased hematocrit at day 15
|
|
|
• significantly greater number of activated CD4+CD44+ T cells in the lymph nodes of both untreated and anti-CD8 antibody treated mutant mice
|
integument
skin lesions
(
J:20865
)
|
|
• untreated and anti-CD8 antibody treated mutants develop skin lesions typical of scurfy disease, while anti-CD4 antibody treated mutants exhibit dramatically reduced lesions
|
